D.E. Shaw & Co
BCRX icon

D.E. Shaw & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

D.E. Shaw & Co’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.88M Sell
302,101
-945,365
-76% -$7.34M ﹤0.01% 2625
2025
Q4 		$9.73M Sell
1,247,466
-461,870
-27% -$3.34M 0.01% 1779
2025
Q3 		$13M Sell
1,709,336
-2,680,141
-61% -$22.3M 0.01% 1479
2025
Q2 		$39.3M Buy
4,389,477
+2,800,365
+176% +$26.1M 0.03% 671
2025
Q1 		$11.9M Buy
1,589,112
+1,273,849
+404% +$10.3M 0.01% 1276
2024
Q4 		$2.37M Buy
315,263
+86,173
+38% +$654K ﹤0.01% 2596
2024
Q3 		$1.74M Sell
229,090
-121,710
-35% -$925K ﹤0.01% 2807
2024
Q2 		$2.17M Buy
350,800
+316,924
+936% +$1.75M ﹤0.01% 2589
2024
Q1 		$172K Buy
33,876
+3,245
+11% +$18.2K ﹤0.01% 3944
2023
Q4 		$183K Buy
+30,631
New +$177K ﹤0.01% 3902
2023
Q3 		– Sell
-10,403
Closed -$73.2K – 4252
2023
Q2 		$73.2K Sell
10,403
-123,320
-92% -$990K ﹤0.01% 3855
2023
Q1 		$1.12M Sell
133,723
-399,530
-75% -$3.85M ﹤0.01% 3089
2022
Q4 		$6.12M Buy
533,253
+37,714
+8% +$470K 0.01% 1894
2022
Q3 		$6.24M Buy
+495,539
New +$6.38M 0.01% 1834
2022
Q2 		– Sell
-519,050
Closed -$8.44M – 5345
2022
Q1 		$8.44M Sell
519,050
-613,215
-54% -$9.84M 0.01% 1761
2021
Q4 		$15.7M Buy
1,132,265
+159,731
+16% +$2.11M 0.01% 1264
2021
Q3 		$14M Buy
972,534
+100,008
+11% +$1.58M 0.01% 1259
2021
Q2 		$13.8M Buy
872,526
+811,723
+1,335% +$11M 0.01% 1240
2021
Q1 		$618K Buy
60,803
+17,163
+39% +$177K ﹤0.01% 3400
2020
Q4 		$325K Buy
+43,640
New +$225K ﹤0.01% 3575
2020
Q2 		– Sell
-36,720
Closed -$73K – 3981
2020
Q1 		$73K Sell
36,720
-1,722,120
-98% -$4.74M ﹤0.01% 3806
2019
Q4 		$6.07M Buy
1,758,840
+101,461
+6% +$255K 0.01% 1582
2019
Q3 		$4.75M Buy
1,657,379
+166,025
+11% +$516K 0.01% 1687
2019
Q2 		$5.65M Buy
1,491,354
+152,659
+11% +$919K 0.01% 1509
2019
Q1 		$10.9M Sell
1,338,695
-160,787
-11% -$1.38M 0.01% 1054
2018
Q4 		$12.1M Sell
1,499,482
-208,837
-12% -$1.62M 0.02% 971
2018
Q3 		$13M Buy
1,708,319
+74,447
+5% +$500K 0.02% 971
2018
Q2 		$9.36M Buy
1,633,872
+669,566
+69% +$3.69M 0.01% 1111
2018
Q1 		$4.6M Buy
964,306
+24,833
+3% +$128K 0.01% 1467
2017
Q4 		$4.61M Sell
939,473
-552,844
-37% -$2.68M 0.01% 1536
2017
Q3 		$7.82M Sell
1,492,317
-595,690
-29% -$3.05M 0.01% 1087
2017
Q2 		$11.6M Sell
2,088,007
-1,065,621
-34% -$6.49M 0.02% 830
2017
Q1 		$26.5M Sell
3,153,628
-529,523
-14% -$3.68M 0.05% 467
2016
Q4 		$23.3M Buy
3,683,151
+18,284
+0.5% +$95.1K 0.04% 564
2016
Q3 		$16.2M Buy
3,664,867
+231,215
+7% +$924K 0.03% 664
2016
Q2 		$9.75M Sell
3,433,652
-621,414
-15% -$1.93M 0.02% 907
2016
Q1 		$11.5M Buy
4,055,066
+1,487,851
+58% +$6.59M 0.02% 779
2015
Q4 		$26.5M Buy
2,567,215
+94,241
+4% +$937K 0.04% 513
2015
Q3 		$28.2M Buy
2,472,974
+304,722
+14% +$4.07M 0.04% 488
2015
Q2 		$32.4M Buy
2,168,252
+444,115
+26% +$5.05M 0.05% 452
2015
Q1 		$15.6M Buy
1,724,137
+53,598
+3% +$555K 0.02% 713
2014
Q4 		$20.3M Sell
1,670,539
-421,822
-20% -$4.66M 0.03% 714
2014
Q3 		$20.5M Sell
2,092,361
-329,857
-14% -$4.04M 0.03% 688
2014
Q2 		$30.9M Buy
2,422,218
+353,158
+17% +$3.44M 0.04% 478
2014
Q1 		$21.9M Sell
2,069,060
-371,117
-15% -$3.96M 0.03% 611
2013
Q4 		$18.5M Buy
2,440,177
+1,617,669
+197% +$10.2M 0.03% 727
2013
Q3 		$5.99M Buy
822,508
+748,058
+1,005% +$3.79M 0.01% 1439
2013
Q2 		$115K Buy
+74,450
New +$128K ﹤0.01% 3858

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

D.E. Shaw & Co's BCRX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its BioCryst Pharmaceuticals (BCRX) stake by 76% in Q1 2026, selling an estimated $7.34M and leaving 302,101 shares worth $2.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2625.

D.E. Shaw & Co first reported a position in BCRX in Q2 2013 and has held it in 48 quarters since. The position peaked at $39.3M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • D.E. Shaw & Co held 302,101 shares of BioCryst Pharmaceuticals worth $2.88M as of Q1 2026.
  • D.E. Shaw & Co sold 945,365 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $7.34M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2625 holding.
  • D.E. Shaw & Co first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
  • D.E. Shaw & Co's BioCryst Pharmaceuticals position peaked at $39.3M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.